These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9735117)

  • 41. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elucidating the elite: mechanisms of control in HIV-1 infection.
    O'Connell KA; Bailey JR; Blankson JN
    Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stem cell transplantation in strategies for curing HIV/AIDS.
    Hütter G
    AIDS Res Ther; 2016; 13(1):31. PubMed ID: 27625700
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy.
    Tissot O; Viard JP; Rabian C; Ngo N; Burgard M; Rouzioux C; Penit C
    AIDS; 1998 May; 12(8):879-84. PubMed ID: 9631141
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children.
    Essajee SM; Kim M; Gonzalez C; Rigaud M; Kaul A; Chandwani S; Hoover W; Lawrence R; Spiegel H; Pollack H; Krasinski K; Borkowsky W
    AIDS; 1999 Dec; 13(18):2523-32. PubMed ID: 10630521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
    Moriuchi H; Moriuchi M
    Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic vaccination in primary HIV infection, the Quest trial.
    Perrin L
    Vaccine; 2002 May; 20(15):2004-6. PubMed ID: 11983263
    [No Abstract]   [Full Text] [Related]  

  • 49. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 and immune control: can we change the course of HIV-1?
    Kovacs A; Connors M
    Lancet; 2004 Mar; 363(9412):833-4. PubMed ID: 15031022
    [No Abstract]   [Full Text] [Related]  

  • 51. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
    Egan MA
    Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
    [No Abstract]   [Full Text] [Related]  

  • 52. Conference underscores differences between AIDS theory and practice.
    AIDS Alert; 1998 Sep; 13(9):97-9. PubMed ID: 11365794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes--a review, hypothesis and implications for treatment.
    Becker Y
    Virus Genes; 2007 Apr; 34(2):93-109. PubMed ID: 17151939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human immunodeficiency virus and acquired immunodeficiency syndrome: an update.
    Schnittman SM; Fauci AS
    Adv Intern Med; 1994; 39():305-55. PubMed ID: 8140958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Questions about HIV causing AIDS? Viral load and T-cell (CD4) counts: why they really matter.
    AIDS Treat News; 2001 May; (364):7-8. PubMed ID: 11569964
    [No Abstract]   [Full Text] [Related]  

  • 59. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.